Company intelligence / Profile preview

Dow Development Laboratories

Petaluma, California, United States

Ownership: Private
Employees: ~39
Development stage: Other

Overview

DDL does not run its own clinical programs but provides end-to-end topical product development and manufacturing services, including successful support for Zoryve (roflumilast) cream for plaque psoriasis approved by the FDA in 2022

Therapeutic areas: Dermatology
Modalities: Small moleculePeptidesProteinsNew chemical entitiesCombination productsGenerics
Industry: Drug Discovery Services

Partnerships

Arcutis Biotherapeutics (support for Zoryve/roflumilast development)

Beyond the preview

Go deeper on Dow Development Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dow Development Laboratories.

Explore the full profile